Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/02—Bacterial antigens
  • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/12—Viral antigens
  • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
  • A61K39/265—Infectious rhinotracheitis virus
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/06—Antiabortive agents; Labour repressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
  • A61P31/22—Antivirals for DNA viruses for herpes viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5252—Virus inactivated (killed)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/525—Virus
  • A61K2039/5254—Virus avirulent or attenuated
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
  • C12N2710/00011—Details
  • C12N2710/16011—Herpesviridae
  • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
  • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
  • C12N2720/00011—Details
  • C12N2720/10011—Birnaviridae
  • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/18011—Paramyxoviridae
  • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
  • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
  • C12N2760/00011—Details
  • C12N2760/18011—Paramyxoviridae
  • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
  • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/24011—Flaviviridae
  • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
  • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
  • C12N2770/00011—Details
  • C12N2770/28011—Hepeviridae
  • C12N2770/28022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

• the present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI 3 ), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo - bovis and Leptospira interrogans pomona by administering to the animal an effective amount of a combination vaccine.
• the combination vaccine can be a whole or partial cell inactivated or modified live preparation.
• BRD bovine respiratory disease
• BRD Bovine Herpes Virus Type-1
• IBR infectious bovine rhinotracheitis virus
• BVDV Bovine viral diarrhea virus
• PI 3 Parainfluenza Virus
• the respiratory form of BRD is characterized by inflammation, swelling, hemorrhage, and necrosis of the mucous membranes of the respiratory tract and may be accompanied by high fever, anorexia, depression, nasal discharge, labored breathing, and inflamed muzzle.
• Abortions induced by IBR and BVDV virus can occur in all three trimesters, but chiefly during the last half of gestation, and often without evidence of other clinical signs (Ellis et al. (1996) JAVMA 208:393-400; Ellsworth et al. (1994) In: Proceedings, 74 th Conference of Research Workers in Animal Disease:34).
• Bovine Herpes Virus Type-1 (BHV-1), is a member of the alphaherpesviridae subfamily, and produces a variety of clinical forms of disease in cattle, including respiratory and genital infections, conjunctivitis, encephalitis, and abortions.
• Previous attempts at controlling BHV-1 infection have utilized vaccines comprising live attenuated virus (Gerber, J. D., et al., 1978, Am. J. Vet. Res. 39:753-760; Mitchell, D., 1974, Can. Vet. Jour. 15:148-151), inactivated virus (Frerichs, G. N., et al., 1982, Vet. Rec.
• viral subunits such as, e.g., one of the three major BHV-1 glycoproteins, which have been designated in the art as gI, gIII, and gIV (Babiuk, L. A., et al., 1987, Virology 159:57-66; van Drunen, S., et al., 1993, Vaccine 11:25-35).
• BHV-1 tgIV a recombinant, truncated version of the BHV-1 gIV glycoprotein (designated in the art as BHV-1 tgIV) to induce mucosal immunity against BHV-1 has been demonstrated (van Drunen, S., et al., 1994, Vaccine, 12:1295-1302).
• the art-recognized BHV-1 vaccines are contraindicated for use in pregnant cattle, seropositive or seronegative, and also contraindicated for use in calves nursing pregnant cows.
• BVDV Types 1 and 2 have been implicated in a variety of clinical syndromes. Studies have established that the virus causes severe primary respiratory disease; that persistently infected (PI) cattle are a major source of infection for susceptible calves; and that BVDV infects white cell reservoirs, causing profound and broad-based deficits in the immune system. Ellis et al. (1996) JAVMA 208:393-400; Baum et al. (1993) The Compendium Collection: Infectious Disease in Food Animal Practice. Trenton, N.J. Veterinary Learning Systems-1 13-121; Meyling et al. (1987) Agric Pestivirus Infect Rumin 225-231.
• BVDV Type 2 once recognized chiefly as a hemorrhagic BVDV isolate mostly in dairy herds, has become the predominant strain isolated in most regions of the United States from both BVD-related abortions and respiratory cases. Van Oirschot et al. (1999) Vet Micro 64:169-183.
• BVDV is classified in the pestivirus genus and Flaviviridae family. It is closely related to viruses causing border disease in sheep and classical swine fever. Infected cattle exhibit “mucosal disease” which is characterized by elevated temperature, diarrhea, coughing and ulcerations of the alimentary mucosa (Olafson, et al., Cornell Vet. 36:205-213 (1946); Ramsey, et al., North Am. Vet. 34:629-633 (1953)). The BVD virus is capable of crossing the placenta of pregnant cattle and may result in the birth of PI calves (Malmquist, J. Am. Vet. Med. Assoc.
• viruses that induce a cytopathic effect cp
• viruses that do not induce a cytopathic effect ncp
• Cp variants can arise from the PI animals preinfected with ncp viruses (Howard et al., Vet. Microbiol. 13: 361-369, 1987; Corapi et al., J. Virol. 62: 2823-2827, 1988).
• BVDV type 1 represents classical or traditional virus strains which usually produce only mild diarrhea in immunocompetent animals
• BVDV type 2 are emerging viruses with high virulence which can produce thrombocytopenia, hemorrhages and acute fatal disease (Corapi et al., J. Virol. 63: 3934-3943; Bolin et al., Am. J. Vet. Res.
• Type I and II BVDV viruses have distinct antigenicity determined by a panel of monoclonal antibodies (Mabs)and by cross-neutralization using virus-specific antisera raised in animals (Corapi et al., Am. J. Vet. Res. 51: 1388-1394, 1990). Viruses of either genotype may exist as one of the two biotypes, cp or ncp virus.
• BVDV vaccines have been developed using chemically inactivated BVD viral isolates (Fernelius et al., Am. J. Vet. Res. 33: 1421-1431, 1972; Kolar et al., Am. J. Vet. Res. 33: 1415-1420, 1972; McClurkin et al., Arch. Virol. 58: 119, 1978). Multiple doses are required for the inactivated viral vaccines to achieve primary immunization. Some inactivated BVDV vaccines provide protection against infection by type I BVDV only (Beer et al., Vet. Microbiology. 77:195-208, 2000). Fetal protection has not been achieved with inactivated BVDV vaccines due to a short duration of immunity and an inefficient cross-type protection (Bolin, Vet. Clin. North Am. Food Anim. Pract. 11: 615-625,1995).
• Modified-live virus (MLV) vaccines offer a higher level of protection.
• licensed BVDV MLV vaccines are produced using attenuated viruses obtained via repeated passage in bovine or porcine cells (Coggins et al., Cornell Vet. 51: 539-, 1961; Phillips et al., Am. J. Vet. Res. 36: 135-, 1975), or using chemically modifiedviruses which exhibit a temperature-sensitive phenotype (Lobmann et al., Am. J. Vet. Res. 45: 2498-, 1984; 47: 557-561, 1986).
• a single dose of MLV vaccine is sufficient for immunization, and duration of the immunity can last for years in vaccinated cattle.
• the protection is against type I virus only.
• the available BVDV vaccines are not indicated for use in pregnant cattle or calves nursing pregnant cows.
• PI 3 virus typically produces only mild disease when acting alone; however, the virus predisposes the respiratory tract to secondary infection with more pathogenic organisms including IBR virus, BRSV, and BVDV, resulting in the classic shipping fever syndrome. Of the various viruses known to cause respiratory disease in cattle, PI 3 virus is the most widespread. Ellis et al. (1996) JAVMA 208:393-400.
• BRSV has a preference for the lower respiratory tract, and severity of infection is determined chiefly by the immune system's response to key viral proteins.
• Leptospirosis caused by spirochetes of the genus Leptospira, is an economically important zoonotic infection of livestock.
• Leptospira borgpetersenii serovar hardjo ( L. hardjo ) and L. interrogans serovar pomona ( L. pomona ) are the two serovars most commonly associated with cattle leptosporosis worldwide.
• L. hardjo L. hardjo
• L. interrogans serovar pomona L. pomona
• Leptospiral infection of cattle may result in acute fever, agalactia, abortion, or birth of premature and weak infected calves, and may contribute to breeding failures and low conception rates. Infections can be treated with antibiotics, but they may be inapparent in cattle that are not lactating or pregnant. In such cattle they establish acute or chronic infection of the kidneys, resulting in urinary shedding of virulent organisms which in turn may infect other animals or their human handlers. Immunity to Leptospira is serovar specific, and although vaccines have been available for many years, most induce only a poor and short-lived immunity.
• the present invention provides vaccines for the treatment and prevention of the major infectious causes of respiratory and reproductive disease in animals, such as cows and calves.
• the present invention further provides immunogenic compositions and methods of treating or preventing diseases or disorders in animals.
• the present invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with at least one of, BVDV Type 1 or Type 2, BHV-1, PI3, BRSV, Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo - bovis and Leptospira interrogans pomona comprising administering to the animal, an effective amount of a combination vaccine.
• the present method provides protection to animals such as bovine, in particular, dairy cattle, against respiratory infection and reproductive disease.
• the present method provides protection to animals such as pregnant cows against abortion caused by IBR and persistent fetal infections caused by BVDV, Types 1 and 2.
• the present method also provides protection to animals such as lactating cows and calves nursing pregnant cows against persistent infections caused by BVDV, Types 1 and 2.
• the present method provides protection to breeding age animals, pregnant animals and lactating animals.
• the combination vaccine employed in the present methods can be a whole or partial cell preparation (e.g., modified live preparation).
• the combination vaccine administered in accordance with the present invention may include additional components, such as an adjuvant and optionally a second or more antigens.
• a second antigen is selected from the following, including, but not limited, to bovine herpesvirus type 1 (BHV-1), bovine viral diarrhea virus (BVDV type 1 or 2), bovine respiratory syncitial virus (BRSV), parainfluenza virus (PI3), Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira bratislava, Campylobacter fetus, Neospora caninum, Trichomonus fetus, Mycoplasma bovis, Haemophilus somnus, Mannheimia haemolytica and Pasturella multocida.
• BHV-1 bovine herpesvirus type 1
• the present invention provides a method of treating or preventing a disease or disorder in an animal caused by infection with IBR, BVDV, PI3, BRSV, Campylobacter fetus and/or Leptospirae by administering to the animal, an effective amount of a combination vaccine.
• the vaccines used in the method of the present invention comprise a modified live vaccine and a pharmaceutically acceptable carrier, or a modified live vaccine and an adjuvant.
• the term “treating or preventing” with respect to a disease or disorder as used herein means reducing or eliminating the risk of infection by a virulent BVDV virus, types I and 2; IBR; P13; BRSV; Campylobacteria; and/or Leptospira antigens, ameliorating or alleviating the symptoms of an infection, or accelerating the recovery from an infection.
• the treatment is considered therapeutic if there is a reduction in viral or bacterial load, decrease in pulmonary infections, reduced rectal temperatures, and/or increase in food uptake and/or growth.
• the treatment is also considered therapeutic if there is a reduction in fetal infection and urinary shedding due to infection with Leptospira serovars hardjo and pomona, for example.
• the method of the present invention is, for example, effective in preventing or reducing abortion caused by IBR and infections caused by BVDV Types 1 and 2, and reducing rectal temperatures.
• the present invention is therefore contemplated to provide fetal protection against IBR and infections caused by BVDV Types 1 and 2 as well as fetal protection against cattle herpes and cattle pestiviruses.
• the present invention is also contemplated to provide protection against persistent fetal infection, such as persistent BVDV infection.
• persistent fetal infection infection occurring during early fetal development (e.g., 45-125 days of gestation) that leads to the live birth of animals that are immunotolerant to BVDV and maintain active BVDV replication and multiplication that often occurs at a high rate for months or years, serving as a permanent source of BVDV in the herd.
• persistently infected animals are also at risk of developing fatal mucosal disease if superinfected with a cytopathic virus biotype.
• a combination vaccine is meant a bivalent or multivalent combination of antigens including modified live antigens and/or inactivated antigens.
• a combination vaccine can comprise modified live infectious IBR, PI3, BRSV and inactivated BVDV Types 1 and 2, one or more antigens such as but not limited to Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira bratislava, Campylobacter fetus, Neospora caninum, Trichomonus fetus, Mycoplasma bovis, Haemophilus somnus, Mannheimia haemolytica and Pasturella mult
• the modified live IBR component is temperature sensitive IBR.
• the BVDV Type 2 component is cytopathic (cpBVD-2 strain 53637-ATCC No. PTA-4859) and the BVDV Type 1 component is cytopathic 5960 (cpBDV-1 strain 5960-National Animal Disease Center, United States Department of Agriculture, Ames, Iowa).
• the present invention also contemplates non-cytopathic BVDV Type 1 and Type 2 strains.
• the modified live antigens are desiccated, lyophilized or vitrified.
• a combination vaccine can comprise inactivated BVDV Types 1 and 2, one or more antigens such as, but not limited to, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira bratislava, Campylobacter fetus, Neospora caninum, Trichomonus fetus, Mycoplasma bovis, Haemophilus somnus, Mannheimia haemolytica and Pasturella multocida, a veterinary acceptable carrier and an adjuvant.
• antigens such as, but not limited to, Leptospira canicola, Leptospira grippotyphosa, Leptospira
• combination vaccine as used herein also refers to a multicomponent composition containing at least one modified live antigen, at least one second antigen and an adjuvant which prevents or reduces the risk of infection and/or which ameliorates the symptoms of infection.
• the second antigen is inactivated.
• the source of the combination vaccine is PregSure® 5 (Pfizer, Inc.), PregSure® 5-L5 (Pfizer, Inc.) and PregSure® 5-VL5 (Pfizer, Inc.).
• a particularly preferred source of the combination vaccine is PregSure® 5-VL5.
• the protective effects of a combination vaccine composition against a pathogen are normally achieved by inducing in the subject an immune response, either a cell-mediated or a humoral immune response or a combination of both.
• an immune response either a cell-mediated or a humoral immune response or a combination of both.
• the vaccine compositions of the present invention provide protection against infections caused by either or both type 1 and type 2 BVD viruses as well as abortions caused by BHV-1 (IBR) and respiratory infections caused by PI3 and BRSV.
• the present method of treating or preventing a disease or disorder in an animal caused by infection with IBR, BVDV, PI3, BRSV, Campylobacter fetus and/or Leptospirae by administering a combination vaccine is also referred to herein as a vaccination method.
• the term “combination vaccine” that may be used in the present method can include, for example, an inactivated whole or partial C. fetus and/or Leptospira cell preparation, inactivated BVDV types 1 and 2 and/or one or more modified live antigens such as BHV-1, PI3 and/or BRSV.
• the vaccine compositions of the present invention include an effective amount of one or more of the above-described BVDV viruses, preferably cpBVD-2 strain 53637 (ATCC No. PTA4859); cpBVD-1 strain 5960 (cpBDV-1 strain 5960-National Animal Disease Center, United States Department of Agriculture, Ames, Iowa);IBR ts mutant strain RBL 106 (National Institute of Veterinary Research, Brussels, Belgium); PI 3 ts mutant strain RBL 103 (RIT, Rixensart, Belgium); BRSV strain 375 (Veterinary Medical Research Institute, Ames, Iowa) Purified BVDV viruses can be used directly in a vaccine composition, or preferably, BVD viruses can be further attenuated by way of chemical inactivation or serial passages in vitro.
• cpBVD-2 strain 53637 ATCC No. PTA4859
• cpBVD-1 strain 5960 cpBDV-1 strain 5960-National Animal Disease Center, United States Department of Agriculture, Ames, Iowa
• a vaccine typically contains between about 1 ⁇ 10 3 and about 1 ⁇ 10 10 plaque or colony forming units of virus, with a veterinary acceptable carrier and an adjuvant, in a volume of between 0.5 and 5 ml and preferably about 2 ml.
• a veterinary acceptable carrier and an adjuvant in a volume of between 0.5 and 5 ml and preferably about 2 ml.
• the precise amount of a virus in a vaccine composition effective to provide a protective effect can be determined by a skilled veterinary physician.
• Veterinary acceptable carriers suitable for use in vaccine compositions can be any of those described hereinbelow.
• the typical route of administration will be intramuscular or subcutaneous injection of between about 0.1 and about 5 ml of vaccine.
• the vaccine compositions of the present invention can also include additional active ingredients such as other vaccine compositions against BVDV, e.g., those described in WO 9512682, WO 9955366, U.S. Pat. No. 6,060,457, U.S. Pat. No. 6,015,795, U.S. Pat. No. 6,001,613, and U.S. Pat. No. 5,593,873.
• Vaccination can be accomplished by a single inoculation or through multiple inoculations. If desired, sera can be collected from the inoculated animals and tested for the presence of antibodies to BVD virus.
• the vaccine compositions are used in treating BVDV infections. Accordingly, the present invention provides methods of treating infections in animal subjects caused by BVD viruses of type 1 or type 2, or a combination of type 1 and type 2, by administering to an animal, a therapeutically effective amount of a BVD virus of the present invention. In another embodiment the vaccine compositions of the present invention are effective for the improvement of herd fertility, and for the reduction of the risk of disease transmission from cattle to human handlers.
• animal subject is meant to include any animal that is susceptible to BVDV, BHV, PI 3 , BRSV or Leptospira infections, for example, such as bovine, sheep and swine.
• a vaccine composition of the present invention is administered to a cattle preferably via intramuscular or subcutaneous routes, although other routes of administration can be used as well, such as e.g., by oral, intranasal (e.g. aerosol or other needleless administration), intra-lymph node, intradermal, intraperitoneal, rectal or vaginal administration, or by a combination of routes.
• Boosting regimens may be required and the dosage regimen can be adjusted to provide optimal immunization.
• immunogenic is meant the capacity of a BVD virus to provoke an immune response in an animal against type 1 or type 2 BVD viruses, or against both type 1 and type 2 BVD viruses.
• the immune response can be a cellular immune response mediated primarily by cytotoxic T-cells, or a humoral immune response mediated primarily by helper T-cells, which in turn activates B-cells leading to antibody production.
• the viruses are preferably attenuated by chemical inactivation or by serial passages in cell culture prior to use in an immunogenic composition.
• the methods of attenuation are well known to those skilled in the art.
• a preferred virus to be included in an immunogenic composition of the present invention is BVDV cp53637(ATCC No. PTA-4859). Another preferred virus to be included in an immunogenic composition of the present invention is BVDV 5960. A further preferred virus to be included in an immunogenic composition of the present invention is IBR strain ts mutant strain RBL 106. Another preferred virus to be included in an immunogenic composition of the present inventions is PI 3 ts mutant strain RBL 103. Yet another preferred virus to be included in an immunogenic composition of the present invention is BRSV strain 375.
• the immunogenic compositions of the present invention can also include additional active ingredients such as other immunogenic compositions against BVDV, e.g., those described in copending application Ser. No. 08/107,908, WO 9512682, WO 9955366, U.S. Pat. No. 6,060,457, U.S. Pat. No. 6,015,795, U.S. Pat. No. 6,001,613, and U.S. Pat. No. 5,593,873.
• additional active ingredients such as other immunogenic compositions against BVDV, e.g., those described in copending application Ser. No. 08/107,908, WO 9512682, WO 9955366, U.S. Pat. No. 6,060,457, U.S. Pat. No. 6,015,795, U.S. Pat. No. 6,001,613, and U.S. Pat. No. 5,593,873.
• the immunogenic and vaccine compositions of the present invention can include one or more veterinary-acceptable carriers.
• a veterinary-acceptable carrier includes any and all solvents, dispersion media, coatings, adjuvants, stabilizing agents, diluents, preservatives, antibacterial and antifungal agents, isotonic agents, adsorption delaying agents, and the like.
• Diluents can include water, saline, dextrose, ethanol, glycerol, and the like.
• Isotonic agents can include sodium chloride, dextrose, mannitol, sorbitol, and lactose, among others.
• Stabilizers include albumin, among others.
• Adjuvants include, but are not limited to, the RIBI adjuvant system (Ribi Inc.), alum, aluminum hydroxide gel, Cholesterol, oil-in water emulsions, water-in-oil emulsions such as, e.g., Freund's complete and incomplete adjuvants, Block co-polymer (CytRx, Atlanta Ga.), SAF-M (Chiron, Emeryville Calif.), AMPHIGEN® adjuvant, saponin, Quil A, QS-21 (Cambridge Biotech Inc., Cambridge Mass.), GPI-0100 (Galenica Pharmaceuticals, Inc., Birmingham, Ala.) or other saponin fractions, monophosphoryl lipid A, Avridine lipid-amine adjuvant, heat-labile enterotoxin from E.
• the RIBI adjuvant system Rostalum, aluminum hydroxide gel, Cholesterol, oil-in water emulsions, water-in-oil emulsions such
• the immunogenic compositions can further include one or more other immunomodulatory agents such as, e.g., interleukins, interferons, or other cytokines.
• the immunogenic compositions can also include Gentamicin and Merthiolate. While the amounts and concentrations of adjuvants and additives useful in the context of the present invention can readily be determined by the skilled artisan, the present invention contemplates compositions comprising from about 50 ⁇ g to about 2000 ⁇ g of adjuvant and preferably about 500 ⁇ g/2 ml dose of the vaccine composition. In another preferred embodiment, the present invention contemplates vaccine compositions comprising from about 1 pg/ml to about 60 ⁇ g/ml of antibiotic, and more preferably less than about 30 ⁇ g/ml of antibiotic.
• the immunogenic compositions of the present invention can be made in various forms depending upon the route of administration.
• the immunogenic compositions can be made in the form of sterile aqueous solutions or dispersions suitable for injectable use, or made in lyophilized forms using freeze-drying techniques. Lyophilized immunogenic compositions are typically maintained at about 4° C., and can be reconstituted in a stabilizing solution, e.g., saline or and HEPES, with or without adjuvant.
• a stabilizing solution e.g., saline or and HEPES
• the immunogenic compositions of the present invention can be administered to animal subjects to induce an immune response against type 1 or type 2 BVD viruses, or against both type 1 and type 2 BVD viruses. Accordingly, another embodiment of the present invention provides methods of stimulating an immune response against type 2 or type 2 BVD viruses, or against a combination of type 1 and type 2 BVD viruses by administering to an animal subject an effective amount of an immunogenic composition of the present invention described above.
• animal subject is meant to include any animal that is susceptible to BVDV infections, such as bovine, sheep and swine.
• a preferred immunogenic composition for administration to an animal subject includes the BVDV cp53637 virus and/or the BVDV cp5960 virus.
• An immunogenic composition containing a BVDV virus preferably attenuated by chemical inactivation or serial passage in culture, is administered to a cattle preferably via intramuscular or subcutaneous routes, although other routes of administration can be used as well, such as e.g., by oral, intranasal, intra-lymph node, intradermal, intraperitoneal, rectal or vaginal administration, or by a combination of routes.
• Immunization protocols can be optimized using procedures well known in the art.
• a single dose can be administered to animals, or, alternatively, two or more inoculations can take place with intervals of two to ten weeks.
• the immunogenic or vaccine composition can be readministered.
• the present invention contemplates the vaccination of healthy cattle prior to six months of age and revaccination at six months of age.
• the present invention contemplates the vaccination of prebreeding cattle at about 5 weeks prebreeding and again at about 2 weeks prebreeding to protect a fetus against infection caused by BVDV Types 1 and 2.
• Semiannual revaccination with a single dose of the combination vaccine is also contemplated to prevent BVDV fetal infection.
• the extent and nature of the immune responses induced in the cattle can be assessed by using a variety of techniques. For example, sera can be collected from the inoculated animals and tested for the presence of antibodies specific for BVDV viruses, e.g., in a conventional virus neutralization assay.
• bovine refers to bovine animals including but not limited to steer, bulls, cows, and calves.
• Cattle refers to pregnant and lactating bovine animals.
• the method of the present invention is applied to an animal which is a non-human mammal; preferably, a lactating or pregnant cow and its fetus.
• the term “therapeutically effective amount” or “effective amount” refers to an amount of combination vaccine sufficient to elicit an immune response in the animal to which it is administered.
• the immune response may comprise, without limitation, induction of cellular and/or humoral immunity.
• the amount of a vaccine that is therapeutically effective may vary depending on the particular virus used, the condition of the cattle and/or the degree of infection, and can be determined by a veterinary physician.
• Inactivated or modified live vaccines for use in the method of the present invention can be prepared using a variety of methods which are known in the art.
• BVDV isolates can be obtained directly from infected cow uteri using known techniques.
• BVDV isolates can be inactivated using a variety of known methods, e.g., treating the bacterial isolate with binary ethyleneimine (BEI) as described in U.S. Pat. No. 5,565,205, or inactivation with formalin, glutaraldehyde, heat, irradiation, BPL, or other inactivating agents known to the art.
• BEI binary ethyleneimine
• a vaccine product can also include an appropriate amount of one or more commonly used adjuvants.
• Suitable adjuvants may include, but are not limited to: mineral gels, e.g., aluminum hydroxide; surface active substances such as lysolecithin; glycosides, e.g., saponin derivatives such as Quil A or GPI-0100; pluronic polyols; polyanions; non-ionic block polymers, e.g., Pluronic F-127 (B.A.S.F., USA); peptides; mineral oils, e.g.
• oil emulsions e.g. an emulsion of mineral oil such as BayolF/Arlacel A and water, or an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum; bovine cytokines; cholesterol; and combinations of adjuvants.
• the saponin containing oil-in-water emulsion is conventionally microfluidized.
• a particularly preferred source of BVDV type 1, for use in the vaccine and method of the present invention is PregSure® (PFIZER INC.), containing BVDV strain 5960 (acquired from the National Animal Disease Center (NADC), USDA, Ames, Iowa).
• a particularly preferred source of BVDV type 2, for use in the vaccine and method of the present invention is PregSure® (Pfizer, Inc.), containing BVDV strain 53637 (ATCC No. PTA-4859), acquired from the University of Guelph, Guelph, Ontario.
• the strains 5960 and 53637 are inactivated with BEI and adjuvanted with a commercially available adjuvant, preferably, Quil A-Cholesterol-Amphigen (Hydronics, USA).
• a preferred dose of the immunogenic and vaccine compositions of the present invention is about 2.0 ml.
• Preservatives can be included in the methods and compositions of the present invention.
• Preservatives contemplated by the present invention include gentamicin and merthiolate.
• a carrier can also be added, preferably, PBS.
• Preparation of modified live vaccines, such as by attenuation of virulent strains by passage in culture, is known in the art.
• Inactivated BVDV isolates can also be combined with the following bacteria and viruses, including but not limited to, bovine herpesvirus type 1 (BHV-1), bovine respiratory syncitial virus (BRSV), parainfluenza virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardjo - prajitno, Leptospira icterohaemmorrhagiae, Leptospira borgpetersenii hardjo - bovis and Leptospira interrogans pomona.
• BHV-1 bovine herpesvirus type 1
• BRSV bovine respiratory syncitial virus
• PI3 parainfluenza virus
• an effective amount of a combination vaccine administered to cattle including pregnant cows and calves nursing pregnant cows provides effective immunity against disease and fetal infection associated with Bovine Viral Diarrhea Virus (Type 1 and 2).
• the combination vaccine is administered to calves in two doses at an interval of about 3 to 4 weeks.
• the first administration is performed when the animal is about 1 to about 3 months of age.
• the second administration is performed about 1 to about 4 weeks after the first administration of the combination vaccine.
• the first administration is performed about 5 weeks prior to animal breeding.
• the second administration is performed about 2 weeks prior to animal breeding.
• Administration of subsequent vaccine doses is preferably done on an annual basis.
• animals vaccinated before the age of about 6 months should be revaccinated after 6 months of age.
• Administration of subsequent vaccine doses is preferably done on an annual basis.
• the amount of combination vaccine that is effective depends on the ingredients of the vaccine and the schedule of administration. Typically, when an inactivated Bovine Viral Diarrhea Virus preparation is used in a vaccine, an amount of the vaccine containing about 10 3 to about 10 10 colony forming units per dose of BVDV, and preferably about 10 5 to about 10 8 colony forming units per dose of BVD V(Type 1 and 2) is effective when administered twice to the animal during a period of about 3 to 4 weeks.
• a combination vaccine that provides effective immunity contains about 10 5 to 10 8 colony forming units/dose of BVDV (Type 1 and 2) and more preferably, about 10 6 colony forming units/dose, when administered twice to the animal during a period of about 3 to 4 weeks.
• the first administration is performed about 5 weeks prior to animal breeding.
• the second administration is performed about 2 weeks prior to animal breeding.
• Administration of subsequent vaccine doses is preferably done on an annual basis. Animals vaccinated before the age of about 6 months should be revaccinated after 6 months of age. Administration of subsequent vaccine doses is preferably done on an annual basis.
• PregSure® 5 when the preferred product, PregSure® 5 (Pfizer, Inc.), is administered, PregSure® 5 is administered preferably twice, each time in the amount of about 0.5 ml to about 5.0 ml, preferably about 1.5 ml to about 2.5 ml, and more preferably, about 2 ml.
• PregSure® 5-L5 or PregSure® 5-VL5 is administered, PregSure® 5-L5 or PregSure® 5-VL5 is administered preferably twice, each time in the amount of about 0.5 ml to about 10.0 ml, preferably about 3 ml to about 7 ml, and more preferably, about 5 ml.
• the first administration is performed about 5 weeks prior to animal breeding.
• the second administration is performed about 2 weeks prior to animal breeding.
• Administration of subsequent vaccine doses is preferably done on an annual basis. Animals vaccinated before the age of about 6 months should be revaccinated after 6 months of age. Administration of subsequent vaccine doses is preferably done on an annual basis.
• administration can be achieved by known routes, including the oral, intranasal, topical, transdermal, and parenteral (e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular).
• parenteral e.g., intravenous, intraperitoneal, intradermal, subcutaneous or intramuscular.
• a preferred route of administration is subcutaneous or intramuscular administration.
• the present invention also contemplates a single primary dose followed by annual revaccination, which eliminates the necessity of administration of additional doses to calves prior to annual revaccination in order to generate and/or maintain immunity against infection.
• the combination vaccine administered in accordance with the present invention can include additional components, such as an adjuvant (e.g., mineral gels, e.g., aluminum hydroxide; surface active substances such as Cholesterol, lysolecithin; glycosides, e.g., saponin derivatives such as Quil A, QS-21 or GPI-0100; pluronic polyols; polyanions; non-ionic block polymers, e.g., Pluronic F-127; peptides; mineral oils, e.g. Montanide ISA-50, carbopol, Amphigen, Alhydrogel, oil emulsions, e.g.
• an adjuvant e.g., mineral gels, e.g., aluminum hydroxide
• surface active substances such as Cholesterol, lysolecithin
• glycosides e.g., saponin derivatives such as Quil A, QS-21 or GPI-0100
• pluronic polyols e
• an emulsion of mineral oil such as BayolF/Arlacel A and water, or an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum; bovine cytokines; and combinations of adjuvants.
• the administration of an effective amount of a combination vaccine administered to cattle at approximately 3 months of age provides effective immunity against respiratory infections and reproductive disease, and reduces abortions.
• the present invention also provides a method of immunizing cattle, including but not limited to cows, calves, and prebreeding heifers, against infection caused by BVDV (types 1 and 2), and respiratory disease attributed to IBR, BVDV (Types 1 and 2), P13, BRSV, campylobacteriosis and leptospiriosis comprising administering to the animal at least one dose, and preferably two doses of the combination vaccine in order to immunize the animal against infection caused by BVD (types 1 and 2), IBR, PI3, BRSV, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia,
• the vaccine is administered subcutaneously. In another preferred embodiment, the vaccine is administered intramuscularly. Moreover, it is preferred that the vaccine dose comprise about 2 ml to about 7 ml, and preferably about 5 ml , each ml containing about 10 3 to about 10 10 colony forming units/per dose of virus. In another preferred embodiment the vaccine comprises about 2 ml, each ml containing about 10 3 to about 10 10 colony forming units per dose of virus.
• the combination vaccine is desirably administered twice to the animal; once at about 1 to about 3 months of age, and once at about 1 to 4 weeks later.
• the present invention also contemplates semiannual revaccinations with a single dose and revaccination prior to breeding.
• the present invention also provides a method of protecting bovine fetuses against fetal infection and persistent fetal infection, comprising administering to the animal at least one dose, and preferably two doses of the combination vaccine in order to immunize the fetus against infection caused by BVD (types 1 and 2), IBR, PI3, BRSV, Leptospira canicola, Leptospira grippotyphosa, Leptospira borgpetersenii hardio - prajitno, Leptospira icterohaemmorrhagia, Leptospira interrogans pomona, Leptospira borgpetersenii hardjo - bovis, Leptospira bratislava, and Campylobacter fetus.
• the combination vaccine is desirably administered twice to the animal, once about five weeks prior to breeding and once at about two weeks prior to breeding.
• the present invention also contemplates that the administration of an effective amount of a combination vaccine administered to animals, and preferably cattle to treat or prevent disorders including persistent fetal infections and reproductive disorders, such as abortions in such animals.
• Animals Fifty-six BVDV seronegative (i.e., having serum neutralization [SN] titers ⁇ 1:2) cows suitable for breeding were obtained from multiple sources and maintained in research isolation facilities for the duration of the study. Each animal was identified with duplicate ear tags, one placed in each ear. New tags were installed in cases where an animal lost an ear tag. Prior to the study, test animals were inoculated with commercial vaccines for leptospirosis, campylobacteriosis (vibriosis), and clostridial infections. Test animals were maintained under supervision of an attending veterinarian, who clinically monitored them on a daily basis.
• Test vaccine The test vaccine was a multivalent, modified live infectious bovine rhinotracheitis (IBR)-parainfluenza 3 (PI3)-respiratory syncytial virus (RSV) vaccine in desiccated form, rehydrated with an inactivated, liquid BVDV vaccine combined with an adjuvant.
• IBR infectious bovine rhinotracheitis
• PI3 parainfluenza 3
• RSV respiratory syncytial virus
• the BVDV component contained the minimum BVDV-1 and -2 immunizing doses, combined with a sterile adjuvant. Potency of the BVDV immunizing antigens was established by calculating the geometric mean titer (GMT) for 8 replicate titrations of the bulk fluid used for vaccine preparation.
• GTT geometric mean titer
• the IBR-PI3-BRSV-BVDV vaccine was administered in 2 mL doses by either intramuscular (IM) or subcutaneous (SC) injection.
• IM intramuscular
• SC subcutaneous
• the desiccated IBR-PI3-RSV vaccine reconstituted with sterile water was used as a placebo, and was given by IM injection.
• Challenge virus A noncytopathic BVDV type 2 field isolate (Strain 94B-5359, obtained from Dr. Hana Van Campen, Wyoming State Veterinary Laboratory, University of Wyoming) was used as a challenge agent. Virus identity was confirmed by SN assay and reverse transcriptase polymerase chain reaction (RT-PCR). The RT-PCR analysis was positive for BVDV type 2 nucleotide sequences for the p125 protein and the 5 untranslated region, and negative for the BVDV type 1 gp53 and p80 conserved sequences.
• Challenge virus potency was established at a GMT of 10 3.2 TCID 50 /mL by 2 replicate titrations made immediately before and after challenge. Challenge inoculum was given intranasally in a 4 mL divided dose, 2 mL per nostril.
• Serologic assays Seologic assays—Serum neutralization titers for BVDV types 1 and 2 were determined by a constant-virus, decreasing-serum assay in bovine cell culture. Serial dilutions of serum were combined with either 50-300 TCID 50 of cytopathic BVDV type 1 strain 5960, or a similar amount of cytopathic BVDV type 2 strain 125c.
• Biometric data analysis To demonstrate protection following challenge, a statistically significant reduction in incidence of maternal and fetal BVDV type 2 infection had to be demonstrated in vaccinated groups (T2 and T3) versus the placebo control group (T1).
• a Fisher's exact test was used to compare incidence of (1) cow viremia during the first 14 days following challenge, (2) BVDV isolation from amniotic fluid, (3) BVDV isolation from fetal tissue and fetal blood following spontaneous abortion or caesarian section, and (4) BVDV-positive fetal tissue immunohistochemistry.
• Serum neutralization titers were analyzed using a mixed linear model with repeated measures. Least squares means from the analysis of variance were used to calculate a geometric mean titer (GMT), which excluded SN data for cows that were not challenged. A probability value of P ⁇ 0.05 was used to determine statistical significance.
• GTT geometric mean titer
• Fetal protection study The 56 test cows were randomly assigned to one of three test groups, an IM placebo group (T1), an IM vaccination group (T2), and a SC vaccination group (T3) as noted in Table 1. Cows were inoculated with either vaccine or placebo on study Day 0 and Day 21. In all cases, the Day 0 inoculation was administered on the left side of the neck, and the Day 21 inoculation was administered on the right side of the neck.
• cows were given feed top-dressed with melengestrol acetate for 14 days.
• all cows received an IM prostaglandin injection (Lutalyse, Pharmacia & Upjohn, Kalamazoo, Mich.) to synchronize estrus.
• Cows which displayed estrus were bred by artificial insemination with certified BVDV-negative semen.
• the pregnancy status of cows was determined by rectal palpation.
• Cow 38 from the T2 group aborted its fetus on Day 156 (at 123 days of gestation, and 37 days after challenge). Paired serum samples were not evaluated, but cow 38 was negative for postchallenge BVDV isolation from peripheral blood and amniotic fluid. The fetus was severely autolyzed. Histopathologic and bacteriologic evaluation of the fetus revealed purulent inflammation of the chorionic and subchorionic connective tissues. Staphylococcus hyicus was isolated from the lung, liver, and thoracic fluid. Negative BVDV isolation and immunohistochemistry results were obtained, indicating that the fetus was not infected as a result of challenge.
• Unknown fetus 3 was macerated and autolyzed. Staphylococcus sp was isolated from the lung, liver, kidney, and stomach contents. Negative BVDV isolation and immunohistochemistry results were obtained for all tissues from the 3 unknown fetuses. All 3 dams were negative for postchallenge BVDV isolation from peripheral blood. Cows 21 and 40 were likewise negative for BVDV isolation from amniotic fluid, but cow 27 had a BVDV-positive amniotic fluid sample. Paired serum samples from the dams were not evaluated.
• Cow 45 from the T2 group aborted its fetus on Day 160 (at 128 days of gestation, and 41 days after challenge). Extensive fetal autolysis was evident. Staphylococcus sp was isolated from the lung, liver, kidney, stomach contents, and placenta. Placentitis with multifocal thrombosis and suppurative vascultisis was present. Serologic assays of thoracic fluid were negative for IBR, bovine viral diarrhea (BVD), and leptospirosis. Negative BVDV isolation and immunohistochemistry results were obtained for all fetal tissues.
• Cow 66 from the T2 group aborted its fetus on Day 195 (at 160 days of gestation, and 76 days after challenge). Marked suppurative inflammation of the placental lamina basement extending from the fetal surface was observed. E. coli and Proteus vulgaris were cultured from the stomach contents and placenta. Paired serum samples and thoracic fluid serology results did not support IBR, BVD, or leptospirosis as an etiology. Negative BVDV isolation and immunohistochemistry results were obtained for all fetal tissues.
• Cow 31 from the T2 group aborted its fetus on Day 295 (at 262 days of gestation, and 176 days after challenge). Histopathologic examination revealed diffuse necropurulent placentitis, necrosis of the chorionic epithelium, and intense neutrophilic inflammation. Gram-negative coccobacilli and rods were cultured from the inflammatory foci. Paired serology results did not support IBR, BVD, or leptospirosis as an etiology. Negative BVDV isolation and immunohistochemistry results were obtained for all fetal tissues.
• BVDV isolation was obtained from PC peripheral blood samples and amniotic fluid obtained from T1 placebo cow 67, which died prior to the conclusion of the study. All fetal tissues from this cow were BVDV isolation and immunohistochemistry positive.
• Postchallenge virus isolation results are shown in Table 4. All 7 T1 placebo cows experienced BVDV viremia, corroborating serologic results indicating that a viable challenge occurred in each of the nonvaccinated animals. Blood samples from all 16 of the T2 and T3 vaccinates were negative for BVDV viremia on each of 8 postchallenge samples. The difference in the rate of PC viremia in T2 and T3 vaccinates versus controls was statistically significantly (P ⁇ 0.0001).
• Amniotic fluid from 2 of 16 (12.5 percent) vaccinates was BVDV positive, versus positive results for 7 of 7 (100 percent) T1 placebo cows, a statistically significant difference (P ⁇ 0.0001).
• Amniotic fluid samples from T3 vaccinates 27 and 60 were positive.
• the fetus from cow 27 was BVDV-negative by virus isolation and immunohistochemistry methods.
• BVDV isolation results were either all positive or all negative for the fetal tissues evaluated from each fetus.
• Immunohistochemistry results were BVDV positive for fetal tissues from 1 of 14 (7.1 percent) T2 and T3 vaccinates (T3 cow 60). All fetal tissues from 6 of 6 (100 percent) T1 placebo cows were BVDV-immunohistochemistry positive, a significantly higher incidence (P ⁇ 0.0001) versus the vaccinates. BVDV immunohistochemistry results were either all positive or all negative for the tissues evaluated from each fetus.
• Table 5 indicates the source of virus isolation and the prechallenge SN titers of the 2 vaccinated cows with positive BVDV isolation results.
• Serologic data indicates that T3 vaccinates 27 and 60 both responded immunologically to vaccination.
• Cow 27 had a BVDV type 2 SN titer at challenge that was lower than the GMT for the T3 group, but the difference was not significant.
• Intramuscular and SC vaccination collectively provided 92.9 percent efficacy against fetal BVDV-2 infection, with negative BVDV isolation results occurring in fetal tissues from 13 of 14 vaccinated cows (Table 4). This compared to a 88.9 percent rate of protection (16 of 18 vaccinates were BVDV-isolation negative) in an earlier test of the same vaccine against fetal challenge with BVDV-1 (see Example 2). In both of these studies, 100 percent fetal infection occurred in nonvaccinated placebo cows, affirming that vaccinates were exposed to a severe challenge of immunity.
• cows (4) evaluated for vaccinated challenged (1) Material (3) Failed Caesarian BVDV isolation Group Treatment (Days 0, 21) (Day 119) death a (2) Abortion b pregnancy c section (1 + 2 + 4) T1 Placebo (IM) 18 7 1 0 1 5 6 T2 Vaccine (IM) 18 8 0 4 0 4 8 T3 Vaccine (SC) 20 8 0 3 2 3 6
• BVDV Bovine viral diarrhea virus
• SN serum neutralizing
• Animals Fifty-nine BVDV seronegative (i.e., having serum neutralization [SN] titers ⁇ 1:2) cows and heifers of breeding age and soundness were obtained from multiple sources and maintained in isolation at research facilities in Kansas for the duration of the study. Each animal was identified with duplicate ear tags, one placed in each ear. New tags were installed in cases where an animal lost an ear tag. Prior to the study, test animals were inoculated with commercial vaccines for leptospirosis, campylobacteriosis (vibriosis), and clostridial infections. Test animals were maintained under supervision of an attending veterinarian, who clinically monitored them on a daily basis.
• Test vaccine The test vaccine was a multivalent, modified live infectious bovine rhinotracheitis (IBR)-parainfluenza 3 (PI3)-respiratory syncytial virus (RSV) vaccine in desiccated form, rehydrated with an inactivated, liquid BVDV vaccine (CattleMaster/PregSure 5, Pfizer Inc, New York, N.Y.). The BVDV component was combined with a sterile adjuvant. Potency of the BVDV immunizing antigen was established by calculating the geometric mean titer (GMT) for 8 replicate titrations of the bulk fluid used for vaccine preparation.
• IBR infectious bovine rhinotracheitis
• PI3 parinfluenza 3
• RSV respiratory syncytial virus
• the IBR-PI3-BRSV-BVDV vaccine was administered in 2 mL doses by either intramuscular (IM) or subcutaneous (SC) injection.
• IM intramuscular
• SC subcutaneous
• the desiccated IBR-PI3-RSV vaccine reconstituted with sterile water was used as a placebo.
• Challenge virus A noncytopathic BVDV type 1 field isolate (Strain 816317, obtained from Dr. E. J. Dubovi, New York State College of Veterinary Medicine, Cornell University) was used as a challenge agent. Virus identity was confirmed by SN and reverse transcriptase polymerase chain reaction (RT-PCR). The RT-PCR analysis was positive for BVDV type 1 nucleotide sequences for the gp53 and p80 proteins and the 5 untranslated region, and negative for the BVDV type 2 p125 sequence. Challenge virus potency was established at a GMT of 10 4.3 TCID 50 per mL by 2 replicate titrations made immediately before and after challenge. Challenge inoculum was given intranasally in a 4 mL divided dose, 2 mL per nostril.
• Serologic assays Seologic assays—Serum neutralization titers for BVDV types 1 and 2 were determined by a constant-virus, decreasing-serum assay in bovine cell culture. Serial dilutions of serum were combined with either 50-300 TCID 50 of cytopathic BVDV type 1 strain 5960, or a similar amount of cytopathic BVDV type 2 strain 125c.
• Virus isolation Postchallenge isolation of BVDV in bovine cell culture was attempted from peripheral cow blood, amniotic fluid, and fetal tissues. A BVDV-positive cell culture was determined by indirect immunofluorescence using goat anti-BVDV polyclonal antibodies. Isolation of BVDV from fetal tissues was also attempted using immunohistochemistry methods previously described. Haines D M, Clark E G, and Dubovi E J. Vet Pathol 1992;29:27-32. Whole blood from cows was drawn from the jugular vein in 5-10 mL samples and placed in heparin-containing tubes for preparation of buffy coat cells used for virus isolation attempts.
• Amniotic fluid was collected under local anesthesia by left-flank laparotomy and aspiration of a 3-5 mL sample from the uterus. Following caesarian section or spontaneous abortion, the eyes, 3 brain sections, spleen, and thymus were aseptically collected from each fetus. Supernatant from homogenized fetal tissues was used for virus isolation attempts in cell culture. For purposes of immunohistochemistry evaluation, fetal tissues were embedded in paraffin and tested in duplicate using 1:800 and 1:600 ascites dilutions containing anti-BVDV monoclonal antibodies.
• Biometric data analysis To demonstrate protection following challenge, a statistically significant reduction in incidence of maternal and fetal infection had to be demonstrated in vaccinated groups (T2 and T3) versus the placebo control group (T1).
• a Fisher's exact test was used to compare incidence of cow viremia and BVDV isolation from amniotic fluid, fetal tissue, and fetal tissue immunohistochemistry. Serum neutralization titers were analyzed using a mixed linear model with repeated measures. Least squares means from the analysis of variance were used to calculate a geometric mean titer (GMT), which excluded SN data for cows that were not challenged. A probability value of P ⁇ 0.05 was used to determine statistical significance.
• GTT geometric mean titer
• Fetal protection study The 59 test animals were randomly assigned to one of three test groups, an IM placebo group (T1), an IM vaccination group (T2), and a SC vaccination group (T3) as noted in Table 6. Cows were inoculated with either vaccine or placebo on study Day 0 and Day 21. In all cases, the Day 0 inoculation was administered on the left side of the neck, and the Day 21 inoculation was administered on the right side of the neck.
• the BVDV type 1 SN titers ranged from 1:27 to 1:2,900, and the BVDV type 2 titers ranged from 1:609 to 1:13,777.
• GMT values for the SC group were marginally higher versus the IM group at each prechallenge interval, but the differences were not statistically significant.
• Cow number 1317 from the T1 placebo group aborted its fetus on Day 238 (after 201 days of gestation, and 121 days after challenge). Histopathologic and bacteriologic evaluation of the fetus revealed pneumonia, necrosis of the chorionic epithelium, and Corynebacterium sp. isolated from the stomach and placenta. Paired serologic samples from the cow did not support IBR, BVD, or leptospirosis as the abortion etiology. Positive BVDV isolation results in cell culture were obtained for peripheral cow blood collected at 6, 8, and 10 days after challenge; for amniotic fluid; and for fetal brain, eye, and thymus, but not the spleen.
• BVDV Fetal brain, eye, thymus, and spleen were immunohistochemistry positive for BVDV. Virus isolation and serologic evidence in this case indicates that a BVDV infected fetus was aborted by a dam that experienced viremia as a result of challenge.
• Cow number 1331 from the T3 vaccine group aborted its fetus on Day 249 (after 212 days of gestation, and 132 days after challenge). Histopathologic and bacteriologic evaluation of the fetus revealed a diffuse purulent pneumonia. Cultures of stomach contents and lung were heavily overgrown with coliform bacteria. Paired post-abortion serologic samples from the cow did not support IBR, BVD, or leptospirosis as the abortion etiology. Attempts at BVDV isolation in cell culture were negative for cow peripheral blood collected at all 9 postchallenge intervals, and for amniotic fluid, and fetal brain, eye, spleen and thymus.
• Postchallenge virus isolation results are shown in Table 9.
• T2 vaccinate 1421 was BVDV positive on Day 123, 6 days after challenge, and delivered a fetus that was seropositive as noted above, but virus-isolation negative.
• the 5 percent incidence of postchallenge BVDV viremia in T2 and T3 vaccinates was significantly less (P ⁇ 0.0001) than the 90 percent rate in controls.
• BVDV isolation results were either BVDV-positive or -negative for all fetal tissues evaluated, with one exception, T1 cow 1317, from which 3 of 4 fetal tissue samples were positive.
• Amniotic fluid from 2 of 20 (10 percent) vaccinates was BVDV positive, versus positive results for 10 of 10 (100 percent) of T1 placebo cows, a statistically significant difference (P ⁇ 0.0001). Amniotic fluid samples from T2 vaccinates 1301 and 1335 were positive.
• Cortese VS Bovine virus diarrhea virus and mucosal disease. In: Current Veterinary Therapy 4, Food Animal Practice. Philadelphia, Pa.: WB Saunders, 1999;286-291.
• Cow pre-challenge serum neutralization (SN) titers in cases where bovine viral diarrhea virus (BVDV) was isolated from vaccinated cows or their fetuses BVDV serotype and reciprocal SN titer at challenge Test Source of group Cow no. virus isolation BVDV1 BVDV2 T2 1301 FT, AF, IHC 128 181 T2 1335 FT, AF, IHC 109 91 T2 1421 CV 64 a 27 a T2 Group GMT N/A 177.4 174.8
• Test vaccines The experimental test vaccines were liquid vaccines containing either formalin inactivated L. hardjo - bovis or L. pomona, or both, and inactivated BVD type 1 and type 2 viruses. The BVDV components were combined with a sterile adjuvant. Potency of the BVDV immunizing antigens was established by calculating the geometric mean titer (GMT) for 8 replicate titrations of the bulk fluid used for vaccine preparation. Potency of the Leptospira immunizing antigens was established in accordance with a hamster lethality model procedure.
• GTT geometric mean titer
• the adjuvants in the experimental test vaccines were comprised of either 2.5% Amphigen (v/v) with Quil A/cholesterol each at 100 mcg/ml, with or without 2% (v/v) aluminum hydroxide; 2.5% Amphigen (v/v) with Quil A/Dimethyl dioctadecylammonium bromide (DDA) each at 100 mcg/ml, with or without 2% (v/v) aluminum hydroxide.
• the experimental test vaccines were administered in 5 mL dose by subcutaneous (SC) injection.
• a monovalent L. hardjo - bovis bacterin was used as a positive control per manufacturer's instructions.
• a placebo vaccine containing physiological saline was used as a negative control.
• Challenge bacteria Leptospira borgpetersenii serovar hardjo type hardjo - bovis strain 203 (National Animal Disease Center, Ames, Iowa), was used as the challenge agent.
• L. hardjo - bovis challenge material was prepared as first passage organisms which had been isolated from the urine of cattle experimentally infected with L. hardjo - bovis. The challenge material was administered once daily for three consecutive days. Each challenge day, a total of two mL of challenge material, containing approximately 2.5 ⁇ 10 6 L. hardjo - bovis organisms/mL, was administered across three separate anatomical sites. The route of challenge was instillation into the conjunctival sac of each eye (1 ⁇ 2 mL each) and into the vagina (1 mL).
• Serologic assays Serum neutralization titers for BVDV types 1 and 2 were determined by a constant-virus, decreasing-serum assay in bovine cell culture. Serial dilutions of serum were combined with either 50-300 TCID 50 of cytopathic BVDV type 1 strain 5960, or a similar amount of cytopathic BVDV type 2 strain 1 25c. Serum microscopic agglutination titers (MAT) for L. hardjo - bovis and L. pomona were conducted using a standard test at a qualified veterinary diagnostic center (Cornell University College of Veterinary Medicine Diagnostic Laboratory).
• Leptospira isolation Urine samples and kidney tissue homogenates (pooled left and right kidney) were examined for the presence of Leptospira. Urine and kidney cultures were examined for Leptospira once weekly for up to 8 weeks using standard procedures. Leptospira fluorescent antibody (FA) techniques were conducted using a standard test at a qualified veterinary diagnostic center (Cornell University College of Veterinary Medicine Diagnostic Laboratory).
• Leptospira protection study The 36 test animals were randomly assigned to one of six test groups as indicated in Table 11. On Day 0 and Day 21, each animal assigned to T01-T05 received one 5 mL SC dose of the appropriate experimental test or placebo vaccine. On Day 0 and Day 28, each animal assigned to T06 received one 2 mL SC dose of the positive control vaccine. On Days 57-59, all animals were challenged with L. hardjo-bovis strain 203 as outlined above.
• Urine samples (approximately 45 mL) were collected from each animal on Days—1, 56, 70, 77, 84, 91, 98 and 105 for leptospire isolation as described above.
• the GMT values indicate that all the animals receiving BVDV-Leptopsira combination vaccines (T02, T03, T04 and T05) elicited a serologic response following administration of two vaccine doses. All the animals in groups T02, T03, T04 and T05 seroconverted (SN titer ⁇ 1:8) to BVDV type 1 following the second vaccine dose. All the animals in groups T02, T04 and T05 seroconverted (SN titer ⁇ 1:8) to BVDV type 2 following the second vaccine dose. All cows in the placebo group (T01) or in the group that received monovalent L.
• BVDV serology data shows for the first time that combination vaccines comprising inactivated BVDV types 1 and 2 and inactivated L. hardjobovis and L. pomona formulated in four different adjuvants can induce a protective response against BVDV disease in cattle, since a cow BVDV SN titer of ⁇ 1:8 is known in the art to be indicative of protection against BVDV disease.
• hardjobovis isolation data shows for the first time that combination vaccines comprising inactivated BVDV types 1 and 2 and inactivated L. hardjobovis and L. Pomona formulated in four different adjuvants can induce a protective response against Leptospira disease in cattle.
• Animals Twenty BVDV seronegative (i.e., having serum neutralization [SN] titers ⁇ 1:2) cows were obtained and maintained in research isolation facilities for the duration of the study. Each animal was identified with duplicate ear tags, one placed in each ear. New tags were installed in cases where an animal lost an ear tag. Test animals were maintained under supervision of an attending veterinarian, who clinically monitored them on a daily basis.
• Test vaccine was a multivalent, modified live infectious bovine rhinotracheitis (IBR)-parainfluenza 3 (PI3)-respiratory syncytial virus (RSV) vaccine in desiccated form, rehydrated with an inactivated, liquid 8-way BVDV-Leptospira spp- Campylobacter fetus containing vaccine in a Quil A/cholesterol/Amphigen adjuvant. (Pfizer Inc, New York, N.Y.) The liquid composition consisted of inactivated BVDV-1 and -2 viruses, five inactivated Leptospira species ( L. canicola, L. grippotyphosa, L.
• Control vaccine consisted of the five inactivated Leptospira spp. described above and inactivated C. fetus bacterin combined with a sterile mineral oil (Drakeol) adjuvant.
• Test vaccine was given by subcutaneous injection and control vaccine was given by intramuscular injections. Vaccines were administered on Day 0 on the right side of the neck and on Day 21 on the left side of the neck.
• Challenge virus A cytopathic BVDV type 2 field isolate (Strain 24515) was used as a challenge agent.
• Challenge virus potency was established at a GMT of 10 5.4 TCID 50 /5 mL by 2 replicate titrations made immediately before and after challenge.
• Challenge inoculum was given intranasally on Day 42 in a 5 mL divided dose, approximately 2.5 mLs per nostril.
• Serologic assays Serologic assays—Serum neutralization titers for BVDV types 1 and 2, BHV-1, P13 and BRSV were determined by a constant-virus, decreasing-serum assay in bovine cell culture using standard procedures. C. fetus antibody titers were determined by a standard agglutination assay.
• PC peripheral white blood cells
• Clinical Disease Scoring Each animal was scored on Days 40-56 post-challenge. A normal animal with no clinical signs received a score of zero. An animal with nonspecific clinical signs (eg nasal discharge, abnormal respiration, and lethargy) not specific for acute BVD virus infection received a score of one. A score of two was assigned to any animal with acute BVD clinical disease in which clinical signs as a whole were moderate and specific for acute BVD virus infection. Clinical signs include nasal discharge, abnormal respiration, lethargy, gauntness, ocular discharge, hypersalivation, diarrhea, dehydration, lameness and/or reluctance to move. An animal with clinical signs that as a whole were severe in degree was assigned a score of three.
• Biometric data analysis For serum virus neutralization, titers were transformed to log base 2 and analyzed by a mixed linear model with repeated measures. Backtransformation was done to calculate geometric mean titer (GMT). Percent number of days with positive virus isolation was anluzed using a mixed linear model. Pairwise comparison of test versus control vaccine groups were made. A probability value of P ⁇ 0.05 was used to determine statistical significance.
• fetus Vaccine Components 0 35 0 35 0 35 0 35 0 35 0 35 0 35 0 35 Control 5 Leptospira 1 1 a 1 1 a 1 1 a 140 175 8 14 57 260 spp., C. fetus Test BHV-1, PI3 1 8 b 1 18 b 1 145 b 155 453 16 57 26 422 BRSV, BVDV-1 BVDV-2 5 Leptospira spp., C. fetus
• Results show that the 11-way test vaccine composition was immunogenic in cattle since differences in antibody titers to all 5 viruses were observed between pre-vaccination (Day 0) and post-vaccination (Day 35) timepoints.
• post-vaccination (Day 35) titers to C. fetus were similar between the 5-way control and 11-way test vaccine, demonstrating that the presence of the modified-live and killed viral fractions in the 11-way vaccine did not interfere with ability of the host to mount an immune response against the C. fetus bacterial fraction.
• Test vaccine The test vaccines were prepared by reconstituting the lyophilized modified live virus vaccine CattleMasterTM, containing modified live infectious bovine rhinotracheitis (IBR)-parainfluenza 3 (PI3)-respiratory syncytial virus (RSV) with one of the killed BVD liquid diluents (containing BVDV types 1 and 2) prepared in a microfluidized saponin-based (Quil A or GPI-0100) oil-in-water emulsion.
• IBR infectious bovine rhinotracheitis
• PI3 parainfluenza 3
• Vaccines were administered as a single 2 mL dose subcutaneously (SC) on the right side of the neck for the first administration (Day 0 and/or Day 2) and on the left side of the neck for the second administration (Day 21). Injections were administered in the lateral neck approximately midway between the scapula and the poll.
• SC subcutaneously
• Challenge virus The challenge virus was non-cytopathic Bovine Viral Diarrhea virus (BVDV) Type 2, strain 24515.
• BVDV Bovine Viral Diarrhea virus
• BVDV Bovine Viral Diarrhea virus
• a 5 mL dose of the challenge virus preparation (approximately 2.5 mL per nostril) was administered intranasally (needle-less syringe administration) to animals in treatments T01, T02, T03 and T04.
• the challenge material was titrated for virus content (two replicates per assay) prior to and following challenge administration.
• the mean titers pre-challenge and post-challenge were 5.5 log 10 and 5.3 log 10 per 5 mL dose, respectively.
• Serologic assays Boood samples (two 13 mL SST tubes) for BVD serology were collected o Days 0, 21, 35, 43, and 57. Serum neutralization titers for BVDV types 1 and 2, BHV-1, were determined by a constant-virus, decreasing-serum assay in bovine cell culture using standard procedures.
• Virus isolation Bood samples (one 8 mL CPT tube) for BVD virus isolation were collected from T01-T04 on Day 43 (prior to challenge) and on Days 44-57.
• a BVDV-positive cell culture was determined by indirect immunofluorescence using goat anti-BVDV polyclonal antibodies
• Clinical Disease Scoring Clinical Disease scores of 0, 1, 2, or 3 based on clinical signs attributable to BVD 2 infection (see above, example 4), were made for each animal T01-T04 on Days 41 through 43 (prior to challenge) and Days 44 through 57.
• Biometric data analysis For serum virus neutralization, titers were transformed to log base 2 and analyzed by a mixed linear model with repeated measures. Backtransformation was done to calculate geometric mean titer (GMT). Percent number of days with positive virus isolation was analyzed using a mixed linear model. Pairwise comparison of test versus control vaccine groups were made. A probability value of P ⁇ 0.05 was used to determine statistical significance.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Virology (AREA)
• Organic Chemistry (AREA)
• Immunology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Engineering & Computer Science (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Biochemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biotechnology (AREA)
• Pulmonology (AREA)
• Reproductive Health (AREA)
• Endocrinology (AREA)
• Pregnancy & Childbirth (AREA)
• Gynecology & Obstetrics (AREA)
• Toxicology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicinal Preparation (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=31946951

Family Applications (4)

Family Applications After (3)

Country Status (32)

Cited By (16)

Families Citing this family (20)

Citations (5)

Family Cites Families (17)

• 2003
  • 2003-08-14 BR BR0313806-2A patent/BR0313806A/pt not_active Application Discontinuation
  • 2003-08-14 OA OA1200500058A patent/OA12915A/en unknown
  • 2003-08-14 RS YUP-2005/0177A patent/RS20050177A/sr unknown
  • 2003-08-14 CN CNB038203162A patent/CN1315534C/zh not_active Expired - Lifetime
  • 2003-08-14 ME MEP-2009-213A patent/ME00810B/fr unknown
  • 2003-08-14 KR KR1020057003230A patent/KR20050062542A/ko not_active Ceased
  • 2003-08-14 EP EP06122758A patent/EP1743652B1/fr not_active Expired - Lifetime
  • 2003-08-14 NZ NZ538394A patent/NZ538394A/en not_active IP Right Cessation
  • 2003-08-14 CA CA2496750A patent/CA2496750C/fr not_active Expired - Lifetime
  • 2003-08-14 AU AU2003263390A patent/AU2003263390B2/en not_active Expired
  • 2003-08-14 AP AP2005003238A patent/AP2005003238A0/xx unknown
  • 2003-08-14 NZ NZ565206A patent/NZ565206A/en not_active IP Right Cessation
  • 2003-08-14 WO PCT/IB2003/003633 patent/WO2004017990A1/fr active Application Filing
  • 2003-08-14 AT AT06122758T patent/ATE533506T1/de active
  • 2003-08-14 MX MXPA05002255A patent/MXPA05002255A/es active IP Right Grant
  • 2003-08-14 UA UAA200501771A patent/UA94689C2/ru unknown
  • 2003-08-14 EA EA200500275A patent/EA011578B1/ru not_active IP Right Cessation
  • 2003-08-14 EP EP03792580A patent/EP1536830A1/fr not_active Ceased
  • 2003-08-14 JP JP2004530459A patent/JP2006501237A/ja active Pending
  • 2003-08-14 KR KR1020067022893A patent/KR20060116037A/ko not_active Ceased
  • 2003-08-14 PL PL375548A patent/PL216541B1/pl unknown
  • 2003-08-20 TW TW092122872A patent/TWI272105B/zh not_active IP Right Cessation
  • 2003-08-22 UY UY27948A patent/UY27948A1/es not_active Application Discontinuation
  • 2003-08-22 PE PE2003000857A patent/PE20040420A1/es not_active Application Discontinuation
  • 2003-08-25 PA PA20038581101A patent/PA8581101A1/es unknown
  • 2003-08-25 AR ARP030103054A patent/AR041047A1/es unknown
  • 2003-08-25 GT GT200300180A patent/GT200300180A/es unknown
  • 2003-08-26 US US10/647,919 patent/US20040081666A1/en not_active Abandoned
• 2005
  • 2005-01-27 IS IS7672A patent/IS7672A/is unknown
  • 2005-02-03 NO NO20050603A patent/NO20050603L/no not_active Application Discontinuation
  • 2005-02-09 ZA ZA200501171A patent/ZA200501171B/en unknown
  • 2005-02-25 MA MA28121A patent/MA27388A1/fr unknown
  • 2005-02-25 TN TNP2005000059A patent/TNSN05059A1/fr unknown
  • 2005-02-28 HR HRP20050192AA patent/HRP20050192B1/hr not_active IP Right Cessation
  • 2005-11-18 HK HK05110344A patent/HK1078457A1/xx not_active IP Right Cessation
• 2007
  • 2007-08-30 US US11/897,421 patent/US20070298053A1/en not_active Abandoned
• 2008
  • 2008-12-16 AU AU2008258154A patent/AU2008258154B2/en not_active Expired
• 2009
  • 2009-05-14 HR HR20090271A patent/HRP20090271A2/xx not_active Application Discontinuation
  • 2009-05-15 JP JP2009118662A patent/JP2009215309A/ja not_active Withdrawn
• 2010
  • 2010-06-22 US US12/820,566 patent/US9662384B2/en active Active
• 2011
  • 2011-12-16 JP JP2011275303A patent/JP5785073B2/ja not_active Expired - Lifetime
• 2012
  • 2012-12-28 US US13/729,206 patent/US20130129779A1/en not_active Abandoned
• 2015
  • 2015-06-03 JP JP2015113008A patent/JP2015172069A/ja active Pending

Patent Citations (5)

Also Published As

Similar Documents

Legal Events